These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19337200)

  • 1. The biological basis for immunotherapy in patients with chronic myelogenous leukemia.
    Pinilla-Ibarz J; Shah B; Dubovsky JA
    Cancer Control; 2009 Apr; 16(2):141-52. PubMed ID: 19337200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological therapy and the immune system in patients with chronic myeloid leukemia.
    Rohon P
    Int J Hematol; 2012 Jul; 96(1):1-9. PubMed ID: 22661045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can increased immunogenicity in chronic myeloid leukemia improve outcomes?
    Chan O; Talati C; Sweet K; Pinilla-Ibarz J
    Expert Rev Hematol; 2019 Apr; 12(4):225-233. PubMed ID: 30855193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunology and immunotherapy of chronic myeloid leukemia.
    Ilander M; Hekim C; Mustjoki S
    Curr Hematol Malig Rep; 2014 Mar; 9(1):17-23. PubMed ID: 24390549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of chronic myeloid leukemia: present state and future prospects.
    Vonka V
    Immunotherapy; 2010 Mar; 2(2):227-41. PubMed ID: 20635930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapeutic strategies in chronic myeloid leukemia.
    Clark RE
    Curr Hematol Malig Rep; 2007 May; 2(2):89-94. PubMed ID: 20425356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunology of chronic myeloid leukemia: current concepts and future goals.
    Vonka V; Petráčková M
    Expert Rev Clin Immunol; 2015 Apr; 11(4):511-22. PubMed ID: 25728856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CML vaccines as a paradigm of the specific immunotherapy of cancer.
    Pinilla-Ibarz J; Cathcart K; Scheinberg DA
    Blood Rev; 2000 Jun; 14(2):111-20. PubMed ID: 11012250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination for leukemia.
    Molldrem JJ
    Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):13-8. PubMed ID: 16399579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia.
    Schwartz J; Pinilla-Ibarz J; Yuan RR; Scheinberg DA
    Semin Hematol; 2003 Jan; 40(1):87-96. PubMed ID: 12563615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient.
    Oji Y; Oka Y; Nishida S; Tsuboi A; Kawakami M; Shirakata T; Takahashi K; Murao A; Nakajima H; Narita M; Takahashi M; Morita S; Sakamoto J; Tanaka T; Kawase I; Hosen N; Sugiyama H
    Eur J Haematol; 2010 Oct; 85(4):358-60. PubMed ID: 20633041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in immunotherapy of chronic myeloid leukemia CML.
    Held SA; Heine A; Mayer KT; Kapelle M; Wolf DG; Brossart P
    Curr Cancer Drug Targets; 2013 Sep; 13(7):768-74. PubMed ID: 23906051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Definition of immunogenic antigens in chronic myeloid leukemia (CML) towards the development of cancer vaccines.
    Schmitt M; Greiner J
    Leuk Res; 2005 Dec; 29(12):1367-9. PubMed ID: 16135383
    [No Abstract]   [Full Text] [Related]  

  • 14. Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia.
    Greiner J; Schmitt M
    Eur J Haematol; 2008 Jun; 80(6):461-8. PubMed ID: 18284627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenic antigens as therapeutic targets against myeloid leukaemic cells.
    Hofmann S; Greiner J
    Leuk Res; 2010 Jul; 34(7):850-1. PubMed ID: 20359745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities.
    Fernandez HF; Kharfan-Dabaja MA
    Cancer Control; 2009 Apr; 16(2):153-7. PubMed ID: 19337201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
    Kessler JH; Bres-Vloemans SA; van Veelen PA; de Ru A; Huijbers IJ; Camps M; Mulder A; Offringa R; Drijfhout JW; Leeksma OC; Ossendorp F; Melief CJ
    Leukemia; 2006 Oct; 20(10):1738-50. PubMed ID: 16932347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.